NASDAQ : KYNB
Kyntra Bio, Inc. — Key statistics
United States
Last price 4.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 18.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 18.50M |
| Enterprise Value | -72.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.05M |
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | +0.32% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 2.04% |
| Owned by Institutions (%) | 12.88% |
| Float | 3.57M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 0.10 |
| Forward PE | n/a |
| PS Ratio | 4.01 |
| Forward PS | 2.70 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.69 |
| Quick Ratio | 2.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.41 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.50% |
| Return on Invested Capital (ROIC) | -68.57% |
| Return on Capital Employed (ROCE) | -77.26% |
| Weighted Average Cost of Capital (WACC) | 10.04% |
| Revenue Per Employee | $135,765 |
| Profits Per Employee | $5.39M |
| Employee Count | 34 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 7.50 |
Taxes
| Measure | Value |
|---|
| Income Tax | -1,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -58.11% |
| 50-Day Moving Average | 6.68 |
| 200-Day Moving Average | 7.10 |
| Relative Strength Index (RSI) | 26.92 |
| Average Volume (20 Days) | 23,932 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 94,984 |
| Short Previous Month | 100,040 |
| Short % of Shares Out | 2.35% |
| Short % of Float | 2.66% |
| Short Ratio (days to cover) | 3.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.62M |
| Gross Profit | -22.58M |
| Operating Income | -50.25M |
| Pretax Income | -30.91M |
| Net Income | 183.19M |
| EBITDA | -50.04M |
| EBIT | -50.25M |
| Earnings Per Share (EPS) | $45.27 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 91.32M |
| Total Debt | n/a |
| Net Cash | 91.32M |
| Net Cash Per Share | $22.55 |
| Equity (Book Value) | -8.14M |
| Book Value Per Share | -7.44 |
| Working Capital | 60.79M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -38.05M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 213,000 |
| Net Borrowing | -80.56M |
| Free Cash Flow | -38.06M |
| FCF Per Share | -$9.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,088.56% |
| Pretax Margin | -669.71% |
| Profit Margin | 3,968.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
| Earnings Yield | 990.51% |
| FCF Yield | -205.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $38.50 |
| Price Target Difference | 742.45% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 3.84% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -24.36 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |